Here's a concise summary for retail investors: **1. Business Performance:** Mastek reported Q4FY26 revenue of ₹938.0 Cr, a 3.6% YoY increase, and full-year FY26 revenue of ₹3,698.8 Cr, up 7.0% YoY.

Net Profit for Q4FY26 jumped 30.9% YoY to ₹106.2 Cr, with full-year Net Profit at ₹404.0 Cr (up 7.5% YoY). Operating EBITDA margins stood at 16.1% for the quarter and 15.8% for the full year.

The UK business led growth in FY26, particularly in healthcare, which surged 95% YoY.

North America shows early positive signs for recovery. **2. Growth Drivers or Strategy:** The company's "Lead with AI" strategy is a key growth driver, evidenced by closing over 25 new AI deals in Q4 and 85+ for the full year, contributing to a 12% improvement in revenue per employee and stable EBITDA margins.

Leadership depth has been strengthened with new CFO and CHRO appointments. **3. Recent Developments:** Mastek's 12-month order backlog grew 24.4% YoY to ₹2,849.2 Cr, reflecting strong revenue visibility.

The Board has proposed a final dividend of ₹16 per share, bringing the total for FY26 to 480%. Noteworthy client wins include establishing the UK's first AI Centre of Excellence for a global financial services provider and implementing a unified patient data system for a US Federal health authority.

Cash balance rose to ₹938.5 Cr. **4. Management Commentary / Outlook:** Management is confident, noting "FY26 has been a year of resetting our foundations" and sees "improved visibility and a clear path to accelerated growth" for FY27, backed by strong client relationships and deal pipeline.